Form 8-K

8-K — PHIBRO ANIMAL HEALTH CORP

Accession: 0001104659-26-049485

Filed: 2026-04-27

Period: 2026-04-27

CIK: 0001069899

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — tm2612861d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2612861d1_ex99-1.htm)

GRAPHIC (tm2612861d1_ex99-1img01.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2612861d1_8k.htm · Sequence: 1

false

0001069899

2026-04-27

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): April 27, 2026

Phibro

Animal Health Corporation

(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)

Delaware

001-36410

13-1840497

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

Glenpointe

Centre East, 3rd Floor

300

Frank W. Burr Boulevard, Suite 21

Teaneck,

New Jersey 07666-6712

(Address of Principal Executive Offices, including

Zip Code)

(201)

329-7300

(Registrant’s telephone number, including

area code)

Not Applicable

(Former name or former address, if changed

since last report)

Securities registered

pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Class

A Common Stock, $0.0001 par value per share

PAHC

NASDAQ

Stock Market

Check the appropriate box below if this Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark

whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule

12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging

growth company ¨

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ¨

ITEM 7.01 REGULATION FD DISCLOSURE.

On April 27, 2026, Phibro Animal Health Corporation (the “Company”),

issued a press release regarding Ordinance No. 1617, published on April 27, 2026 by the Brazilian Ministry of Agriculture and Livestock

(MAPA), prohibiting the importation, manufacture, marketing and use of performance enhancing feed additives containing antimicrobials

classified as important in human or veterinary medicine, including Phibro’s virginiamycin and bacitracin products. This prohibition

will come into effect after a transition period of 180 days from the date of the Ordinance. During such transition period, companies and

customers may continue to use and sell the products under their current labels. The Company has been actively engaged with MAPA on new

registrations of virginiamycin for therapeutic use in cattle and broiler chickens, which are in the final stages of review and approval

by MAPA and are expected during the transition period. The Company’s bacitracin product already carries therapeutic claims in Brazil.

Based on the 180 day transition period, the Company expects the regulatory change to have limited impact on its fiscal year 2026 results.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Item 7.01 and in the press release

is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of, or otherwise regarded as filed under,

the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference into

any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference

in such filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

Exhibit

Number

Description

99.1

Press Release, dated April 27, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

PHIBRO ANIMAL HEALTH CORPORATION

Registrant

Date: April 27, 2026

By:

/s/ Judith Weinstein

Name:

Judith Weinstein

Title:

Senior Vice President, General Counsel and Corporate Secretary

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2612861d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

For Immediate Release

Phibro Animal Health Corporation Announces Regulatory Framework

Change in Brazil for Antimicrobials

TEANECK, N.J., April 27, 2026 (Business Wire) — Phibro

Animal Health Corporation (Nasdaq: PAHC) today announced expected implementation of a new regulatory framework governing the use of certain

antimicrobials in Brazil that have growth promotion indications.

The Brazilian Ministry of Agriculture and Livestock (MAPA) published

Ordinance No. 1617 on April 27, 2026, prohibiting the importation, manufacture, marketing and use of performance enhancing feed additives

containing antimicrobials classified as important in human or veterinary medicine, including virginiamycin and bacitracin. This regulation

brings Brazil into alignment with regulatory approaches adopted in other global markets. This prohibition will come into effect after

a transition period of 180 days from the date of the Ordinance, during such times companies and customers may continue to use and sell

the products under their current labels.

Phibro is working cooperatively with MAPA and relevant industry associations

to support an orderly transition. The Company has been actively engaged with MAPA on new registrations of virginiamycin for therapeutic

use in cattle and broiler chickens. These registrations are in the final stages of review and approval by MAPA and are expected during

the transition period.

Phibro’s bacitracin product already carries therapeutic claims

in Brazil.

Under the new regulatory framework, following the transition period,

use of the subject antimicrobials will require a veterinary prescription. To support compliance and operational efficiency, Phibro is

making available to the Brazilian market PhibroVet®, a digital platform designed to facilitate the creation, transmission, and management

of veterinary prescriptions and prescription history.

Based on the 180 day transition period, the Company expects the regulatory

change to have limited impact on its fiscal year 2026 results. Additional information will be provided during the Company’s upcoming

earnings call scheduled for May 7, 2026.

About Phibro Animal Health Corporation

Phibro Animal Health Corporation is a leading global diversified animal

health and nutrition company. The Company strives to be a trusted partner to livestock producers, farmers, veterinarians, and consumers

who raise or care for farm and companion animals by providing solutions that help maintain and enhance animal health. For more information,

visit www.pahc.com.

Forward-Looking Statements

DISCLOSURE NOTICES

Forward-Looking Statements: This communication contains forward-looking

statements that are subject to risks and uncertainties. All statements other than statements of historical or current fact included in

this communication are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating

to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking

statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “aim,”

“anticipate,” “believe,” “estimate,” “expect,” “forecast,” “outlook,”

“potential,” “project,” “projection,” “plan,” “intend,” “seek,”

“may,” “could,” “would,” “will,” “should,” “can,” “can have,”

“likely,” the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing

or nature of future operating or financial performance or other events. These statements are not guarantees of future performance or actions.

If one or more of these risks or uncertainties materialize, or if management’s underlying assumptions prove to be incorrect, actual

results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the

date on which they are made. Phibro expressly disclaims any obligation to update or revise any forward-looking statement, whether as a

result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be

found in our Quarterly Report on Form 10-Q and Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking

Statements” and “Risk Factors.” These filings and subsequent filings are available online at www.sec.gov, www.pahc.com,

or on request from Phibro.

Internet Posting of Information: We routinely post information that

may be important to investors in the “Investors” section of our website at www.pahc.com. We encourage investors and potential

investors to consult our website regularly for important information about us.

Contact for Phibro Animal Health Corporation

Phibro Animal Health Corporation

Glenn C. David

Chief Financial Officer

+1-201-329-7300

investor.relations@pahc.com

GRAPHIC

Filename: tm2612861d1_ex99-1img01.jpg · Sequence: 6

Binary file (4527 bytes)

Download tm2612861d1_ex99-1img01.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Apr. 27, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 27, 2026

Entity File Number

001-36410

Entity Registrant Name

Phibro

Animal Health Corporation

Entity Central Index Key

0001069899

Entity Tax Identification Number

13-1840497

Entity Incorporation, State or Country Code

Entity Address, Address Line One

Glenpointe

Centre East, 3rd Floor

Entity Address, Address Line Two

300

Frank W. Burr Boulevard, Suite 21

Entity Address, City or Town

Teaneck

Entity Address, State or Province

Entity Address, Postal Zip Code

07666-6712

City Area Code

201

Local Phone Number

329-7300

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Class

A Common Stock, $0.0001 par value per share

Trading Symbol

PAHC

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration